Zhao Huijia, Huang Qi, Liu Ying-Ao, Wu Wenming
From the Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Pancreas. 2025 Mar 1;54(3):e235-e245. doi: 10.1097/MPA.0000000000002426. Epub 2024 Nov 29.
Mutant KRAS activation occurs in most of pancreatic ductal adenocarcinoma (PDAC), which induce the sensitivity to ferroptosis of PDAC cells, but the underlying mechanism is still poorly understood. Here, we show how KRAS acts in signaling to activate transcription factor FOSL1, which promotes the expression of the iron uptake receptor TFRC. In PDAC cells, repression of TFRC by KRAS/FOSL1 signaling inhibited intracellular iron levels, thereby restricting the occurrence of ferroptosis. Furthermore, the KRAS/FOSL1/TFRC axis can make the PDAC cells vulnerable to alteration of the iron level in the tumor microenvironment. Our study highlights a pivotal mechanism of PDAC ferroptosis through iron metabolism and supports a new therapeutic strategy for PDAC with superior potential.
大多数胰腺导管腺癌(PDAC)中会发生突变型KRAS激活,这会诱导PDAC细胞对铁死亡敏感,但其潜在机制仍知之甚少。在此,我们展示了KRAS如何在信号传导中激活转录因子FOSL1,后者促进铁摄取受体TFRC的表达。在PDAC细胞中,KRAS/FOSL1信号传导对TFRC的抑制作用会降低细胞内铁水平,从而限制铁死亡的发生。此外,KRAS/FOSL1/TFRC轴会使PDAC细胞易受肿瘤微环境中铁水平变化的影响。我们的研究突出了通过铁代谢实现PDAC铁死亡的关键机制,并支持了一种具有卓越潜力的PDAC新治疗策略。